Login

Healthcare

00:00:00
Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks- Gary Phillips, CEO, Pharmaxis Ltd
00:00:00
Paxman AB (OM:PAX) Investor Presentation - Richard Paxman,CEO, Paxman AB (publ)
00:00:00
Patrys CEO & MD, Dr James Campbell
00:00:00
Paragon Care (ASX:PGC) Presentation, FNN Online Investor Event - Phil Nicholl, CEO, Paragon Care Ltd
00:00:00
Paradigm Biopharma – executive interview - Paul Rennie, CEO, co-founder and chairman, Paradigm Biopharmaceuticals Ltd
00:00:00
Executive Interview - Paion - Wolfgang Soehngen, CEO, Paion
00:00:00
Paion advancing its general anesthesia drug candidate - Wolfgang Soehngen, CEO, Paion
00:00:00
Oxurion: Developing Innovative Therapies for Diabetic Eye Disease - Patrik De Haes, CEO, Oxurion
00:00:00
Oventus Medical out to transform the sleep-disordered breathing market with new tech - John Cox , CEO, Oventus Medical Ltd
00:00:00
Orthocell delivers outstanding results in Remplir nerve regeneration trial - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Orthocell's CEO, Paul Anderson & Ticker News Interview - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Orthocell talks appointment of exclusive Australian distributor for Remplir - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Orthocell signs defining licence and distribution agreement - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Orthocell on the cusp of significant growth - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Orthocell raising $3.5 million; adds heavy hitters to register - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:00:00
Pharmaxis extends scarring collaboration after encouraging results - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd

© 2026 Nehu